Effectiveness & Safety of Finerenone in Chinese CKD Patients Without

Status Recruiting

Clinical Trial Summary

Background： This study aimed to evaluate the effectiveness and safety of Finerenone in patients with chronic kidney disease (CKD) without diabetes mellitus(DM), however, evidence based on both clinical trails and real-world data are limited. Methods: Patients with CKD without DM were enrolled in this study from December 2022 to December 2024. In conjunction with the established treatment regimen for chronic kidney disease (CKD), study participants were additionally administered Finerenone. To evaluate the therapeutic impact and safety profile of the intervention, three primary biomarkers were monitored: 24-hour urinary protein (UTP), estimated glomerular filtration rate (eGFR), and serum potassium (sK+). These parameters were closely measured on a monthly basis, starting from the point of enrollment and continuing for a duration of twelve months or possibly longer.

Clinical Trial Description

Chronic Kidney Disease (CKD) is a significant global health issue that leads to end-stage renal disease (ESRD) and is associated with rising healthcare costs and high mortality rates. Its prevalence is increasing due to aging populations and the growing rates of diabetes and hypertension. CKD causes severe complications and significantly impairs patients' quality of life. There are notable disparities in CKD incidence and treatment among different socioeconomic groups, and many healthcare systems struggle with the challenges of managing and funding the disease. In terms of treatment, there is a particular bottleneck in addressing CKD among non-diabetic patients. Currently, the focus for non-diabetic CKD patients is on controlling blood pressure and proteinuria. However, new treatments such as finerenone show promise in reducing CKD progression and cardiovascular risks in diabetic patients. Ongoing research aims to explore the effectiveness of these treatments in non-diabetic CKD patients as well. It is important to note that further studies are required to confirm the safety and efficacy of finerenone in these specific populations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06301022
Study type	Observational
Source	First Affiliated Hospital of Harbin Medical University
Contact
Status	Recruiting
Phase
Start date	December 15, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06386172` - Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm	N/A
Recruiting	`NCT04910867` - APOL1 Genetic Testing Program for Living Donors	N/A
Completed	`NCT03434145` - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases	N/A
Recruiting	`NCT04984226` - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	Phase 2
Active, not recruiting	`NCT05887817` - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	Phase 4
Recruiting	`NCT05318196` - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Terminated	`NCT05022329` - COVID-19 Vaccine Boosters in Patients With CKD	Phase 2/Phase 3
Not yet recruiting	`NCT04925661` - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia	Phase 1
Recruiting	`NCT04961164` - Resistant Starch Prebiotic Effects in Chronic Kidney Disease	N/A
Completed	`NCT05015647` - Low Protein Diet in CKD Patients at Risk of Malnutrition	N/A
Completed	`NCT03426787` - Helping Empower Liver and Kidney Patients	N/A
Recruiting	`NCT06094231` - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study	N/A
Completed	`NCT04363554` - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease	N/A
Recruiting	`NCT04831021` - Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?	N/A
Terminated	`NCT04877847` - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury	N/A
Recruiting	`NCT04422652` - Combination of Novel Therapies for CKD Comorbid Depression	Phase 2
Completed	`NCT05055362` - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study	N/A
Not yet recruiting	`NCT06330480` - Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease	N/A
Recruiting	`NCT03176862` - Left Ventricular Fibrosis in Chronic Kidney Disease	N/A
Terminated	`NCT02539680` - Intestinal Phosphate Transporter Expression in CKD Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effectiveness and Safety of Finerenone in Chinese CKD Patients Without Diabetes Mellitus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms